BioSpace News Archive

Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of MYCAPSSA

OpGen, Inc . today announced that its subsidiary Ares Genetics presented an update on the company’s R&D pipeline during two virtual seminars held on May 22 and on May 24, 2021.

9 Meters Biopharma, Inc. announced today it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced the appointment of Eron S. Kelly as its Corporate President.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors.

180 Life Sciences Corp. announced that as previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. with the SEC on April 19, 2021, on April 16, 2021, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5250 because it had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2020 with the Commission.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated), MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Factor VII deficiency. Catalyst is currently enrolling patients with FVII deficiency in a Phase 1/2 open-label study.

ZygoFix has obtained CE mark for its minimally invasive screwless spinal fusion system for the treatment of chronic back pain, the zLOCK Spinal Fusion System.

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that it has been added as a member of the small-cap Russell 2000® Index, the all-cap Russell 3000® Index, and the Russell Microcap® Index, effective upon the U.S. market open today, June 28, 2021, as part of the 2021 Russell indexes reconstitution.

Lineage Cell Therapeutics Joins Russell 3000 ® and Russell Microcap ® Indexes